Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27627004 | 0.89 | MAPK14 (0.52) | MLYCDHDAC6NAMPTCA2 | |
| SCHEMBL7974335 | 0.85 | ITGB3 (0.60) | CHRM1CHRM4 | |
| SCHEMBL3330915 | 0.84 | SMN1; SMN2 (0.56) | SMYD3CHRM1HDAC6NAMPTCHRM2 | |
| SCHEMBL3192308 | 0.84 | HDAC6 (0.62) | MLYCDHDAC6NAMPTCA2 | |
| SCHEMBL5365652 | 0.83 | SMYD3 (0.57) | SMYD3CHRM1MLYCDHDAC6EP300 | |
| SCHEMBL11248353 | 0.82 | MMP13 (0.63) | SMYD3CHRM1MLYCDHDAC6EP300 | |
| SCHEMBL20615737 | 0.82 | CHRM1 (0.58) | SMYD3CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14797370 | 0.82 | NAMPT (0.53) | MLYCDHDAC6NAMPTCA2 | |
| SCHEMBL3035306 | 0.82 | SMYD3 (0.56) | SMYD3MLYCDHDAC6NAMPTCA2 | |
| SCHEMBL15662741 | 0.79 | EP300 (0.64) | SMYD3MLYCDHDAC6EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150539-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2150539-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008145243-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | SMYD3 4060/4885CHRM1 869/4885MLYCD 1119/4885 |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | SMYD3 3538/4885CHRM1 4055/4885MLYCD 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.